TCF7L2 and non-small cell lung carcinoma: Almost 29.7% of the patients had no clinically applicable mutations of NSCLC, among which, 8% had mutations in CEBPA and RB1, and 6% had TCF7L2 mutations, providing targets for clinical drug development for patients who did not have evidence of drugs.